<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors

October 1, 2015

Lake Forest, CA, October 1, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Company”) today announced the appointment of Robert Hariri, MD, PhD to its Board of Directors.  

Read More


Cryoport Acquires Full IP Rights to CryoportalTM

September 24, 2015

Lake Forest, CA, September 24, 2015 – Cryoport, Inc. (NASDAQ:CYRX) (“Company”) today announced the purchase of certain intellectual property and intellectual property rights to the CryoportalTM operating platform from KLATU Networks, LLC.

Read More


Cryoport Supports Opexa Therapeutics’ Lead Personalized T-Cell Immunotherapy Programs

August 26, 2015

Read More


Cryoport Supports Stemedica’s Ischemic-Tolerant Stem Cell Product Lines

August 18, 2015

Lake Forest, CA, August 18, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution is supporting the worldwide distribution of Stemedica’s ischemic-tolerant stem cell product lines.  

Read More


Cryoport Reports 53% Revenue Growth for the First Quarter of Fiscal Year 2016

August 6, 2015

LAKE FOREST, CA – August 6, 2015 — Cryoport, Inc. (NASDAQ: CYRX) today announced financial results for the three-month period ended June 30, 2015.

Read More


Cryoport to Report First Quarter Fiscal 2016 Financial Results

August 3, 2015

LAKE FOREST, California, August 3, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company will release financial results for the first quarter fiscal year 2016 ended June 30, 2015 on Thursday, August 6 before the market opens.

Read More


Cryoport Provides Cryogenic Logistics Solutions to HemaCare Corporation

July 30, 2015

LAKE FOREST, California, July 30, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company will provide cryogenic logistics solutions to HemaCare Corporation (“HemaCare”), a leading global provider of high-quality biological material to the scientific community.

Read More


Cryoport Completes $6.8 Million Equity Capital Raise

July 29, 2015

Lake Forest, CA, July 29, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, announced today that the Company has completed the sale of common stock and warrants (the "Units") under a registered public offering.  The gross proceeds to Cryoport from the offering, including the partial exercise of the over-allotment option, were approximately $6.8 million, before underwriting discounts and commissions and other offering expenses. 

Read More


Tags: equity capital raise

Cryoport’s Portfolio of Temperature-Managed Clinical Programs Expands to 45 Trials

July 27, 2015

Lake Forest, CA, July 27, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, with markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, is now supporting approximately 45 clinical trials. The majority of these trials are regenerative therapies including an array of CAR T-cell therapies. In total, these immunotherapy trials are expected to contribute as much as $150 million of revenue for Cryoport over the next five years.

Read More


Tags: deep frozen shipping, clincal trials

Cryoport Announces Pricing of Public Offering of Units and Listing on NASDAQ

July 23, 2015

Lake Forest, CA, July 23, 2015 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced the pricing of an underwritten .>public offering of 2,000,000 units at an offering price of $3.25 per unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The common stock and the warrants are immediately separable, and will trade on The Nasdaq Capital Market under the symbols CYRX, and CYRXW, respectively.  The warrants will have a per share exercise price of $3.57, are exercisable immediately and will expire five years from the date of issuance.

Gross proceeds to Cryoport from this offering are approximately $6,500,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cryoport. Cryoport has granted the underwriters a 45-day option to purchase up to an additional 300,000 units to cover over-allotments, if any. The offering is expected to close on July 29, 2015, subject to customary closing conditions.

Read More


Tags: NASDAQ, Public Offering